BioSight
Companies
PROTHENA CORP PUBLIC LTD CO logo

PRTA

NASDAQDUBLIN 2, L2
PROTHENA CORP PUBLIC LTD CO

Prothena develops antibody-based drug candidates targeting protein dysregulation diseases, with a focus on building what it calls a "biology-directed discovery engine." The company has programs in clinical development and collaborations with major pharmaceutical partners including Roche, Bristol Myers Squibb, and Novo Nordisk to advance its pipeline across multiple therapeutic areas.

Price history not yet available for PRTA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar